TITLE

VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR

PUB. DATE
August 2004
SOURCE
Worldwide Biotech;Aug2004, Vol. 16 Issue 8, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the agreement between Vertex Pharmaceuticals Inc. and Mitsubishi Pharma Corp. to develop and commercialize VX-950, Vertex's investigational oral protease inhibitor for the treatment of hepatitis C virus. Payments to be given by Mitsubishi to Vertex as part of the agreement; Statement from Joshua Boger, Vertex chairman and CEO, on the partnership; Capabilities of VX-950.
ACCESSION #
13919628

 

Related Articles

  • Telaprevir.  // Drugs in R&D;2010, Vol. 10 Issue 3, p179 

    Telaprevir (LY 570310; LY-570310; LY570310;MP 424;MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. It is being developed by Vertex Pharmaceuticals and its licensees for the treatment of HCV infections and has recently been...

  • Telaprevir Looks Ever-Better, But Don't Discount Boceprevir. Morrison, Trista // BioWorld Insight;8/16/2010, Vol. 18 Issue 33, p3 

    The article reports on the competition in the development of effective pharmacology for hepatitis C virus (HCV). Accordingly, Vertex Pharmaceuticals Inc. has reported a 75 percent HCV cure rate from the protease inhibitor telaprevir, while the boceprevir from Merck & Co. Inc. has reported a 66...

  • Nearing Telaprevir Endgame, Vertex Bulks up War Chest. Boggs, Jennifer // BioWorld Today;7/31/2009, Vol. 20 Issue 146, p1 

    The article reports on the additional investments achieved by Vertex Pharmaceuticals Inc. in relation to the final development stage of its hepatitis C drug telaprevir as of July 31, 2009. As stated, the company received $160 million in exchange for royalty rights for two protease inhibitors...

  • Telaprevir Data Head to Expanded HCV Market.  // Bioworld Week;8/16/2010, Vol. 18 Issue 33, p4 

    The article reports on the second Phase III trial conducted by the Cambridge, Massachusetts-based Vertex Pharmaceuticals Inc. to its hepatitis C virus (HCV) protease inhibitor called telaprevir, which showed 72% cure rate for the disease.

  • INCIVEK.  // MPR - Residents' Edition;Fall/Winter2011, Vol. 20 Issue 2, pA:6 

    The article offers brief clinical and pharmacological information on Incivek, a hepatitis C virus protease inhibitor with telaprevir for treatment of chronic hepatitis C genotype 1 infection from Vertex Pharmaceuticals Inc.

  • Telaprevir Data Illuminate Path to Expanded HCV Market. Morrison, Trista // BioWorld Today;8/11/2010, Vol. 21 Issue 154, p1 

    The article offers information on the 75 and 72 percent cure rate in the first and second Phase III trials of hepatitis C virus (HCV) protease inhibitor telaprevir from Vertex Pharmaceuticals Inc. It suggests that these findings may help telaprevir in penetrating expanded HCV market consisting...

  • Telaprevir's Response-Guided rial Helps HCV Get Personal. Morrison, Trista // BioWorld Insight;5/31/2010, Vol. 18 Issue 22, p3 

    The article focuses on the concept of Vertex Pharmaceuticals Inc. and Merck & Co. Inc. on using early viral load measurements in the Phase III trials of their Hepatitis C virus (HCV) protease inhibitors, telaprevir and boceprevir. It says that protease inhibitors allowed patients to achieve an...

  • EASL Roundup.  // BioWorld Today;4/28/2009, Vol. 20 Issue 80, p7 

    The article offers a look at additional data presented by the Vertex Pharmaceuticals Inc. from its phase IIb clinical trial of protease inhibitor telaprevir in treatment-experienced hepatitis C virus patients. The final data from Phase IIb trial were similar to previously presented interim data....

  • Vertex Pharmaceuticals to acquire ViroChem Pharma.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p22 

    The article reports on the announcement by Vertex Pharmaceuticals Inc. that it will acquire ViroChem Pharma. The acquisition of ViroChem Pharma will allow Vertex Pharmaceuticals Inc., a biotechnology company, to add two polymerase inhibitors to its hepatitis C virus drug development. Under a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics